Breast Cancer
Filters
Ribociclib (Kisqali) 200mg*63's | Novartis China-Sourced | GLT
China-sourced Novartis Kisqali (ribociclib) 200mg 63 tablets, NMPA-approved & reimbursed for HR+/HER2- breast cancer.
Kadcyla 赫赛莱 Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Roche China Originator | GLT
NMPA-approved Roche Kadcyla 赫赛莱 ado-trastuzumab emtansine (T-DM1) 100mg & 160mg vials, China originator HER2-targeted ADC.
Kadcyla Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Roche EU Originator | GLT
EMA-approved Roche Kadcyla ado-trastuzumab emtansine (T-DM1) 100mg & 160mg vials, EU originator HER2-targeted ADC.
Pivikto (Alpelisib) 150mg 28 Tablets | Novartis India Original | GLT
Pivikto — Novartis India's original alpelisib brand, the most affordable genuine original for PIK3CA-mutated breast...
Piqray (Alpelisib) 150mg 56 Tablets | Novartis Hong Kong Original | GLT
Piqray Hong Kong original — 56 tablets = one 28-day treatment month, Novartis, approved in...
Piqray (Alpelisib) 150mg/200mg Tablets | Novartis Germany Original | GLT
Piqray — the Novartis original PI3Kα inhibitor for PIK3CA-mutated HR+/HER2- breast cancer, German original cartons
Sort
- Recommended
- Price: Low to High
- Price: High to Low
- Newest
- Best Selling